GlassScriptPhysician profile
Eric Lehnert
NPI 1780646125
$7,352.51
in general payments reported to CMS, 2019-2025
35 companies · $1,646 in 2025
The $1,646 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,708 · 2022: $1,443 · 2023: $1,305 · 2024: $1,250 · 2025: $1,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,201.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,258.03 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $762.66 | 2021-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $682.23 | 2021-2025 | Trelegy Ellipta |
| Abbvie INC. | $667.00 | 2021-2025 | |
| Novo Nordisk INC | $646.13 | 2021-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $476.81 | 2021-2025 | |
| Lilly USA, LLC | $401.64 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.16 | 2021-2023 | Tradjenta, Jardiance, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $265.37 | 2022-2025 | Dupixent, Evkeeza |
| Exact Sciences Corporation | $253.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $203.71 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.23 | 2023-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $191.13 | 2021-2022 | |
| Genzyme Corporation | $169.03 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $149.11 | 2021-2025 | Gardasil 9, Capvaxive |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $114.47 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $90.95 | 2025 | |
| Sanofi Pasteur INC. | $77.39 | 2023-2025 | |
| Seqirus USA INC | $55.98 | 2025 | Flucelvax, Fluad |
| Corcept Therapeutics | $39.88 | 2024-2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $39.04 | 2022 | |
| Esperion Therapeutics, INC. | $38.42 | 2021-2024 | Nexletol |
| Althera Pharmaceuticals LLC | $30.39 | 2021 | |
| Boston Scientific Corporation | $30.20 | 2022 | |
| Horizon Therapeutics Plc | $29.09 | 2021 | |
| Inspire Medical Systems, INC. | $22.53 | 2023 | Inspire |
| Azurity Pharmaceuticals, INC. | $20.82 | 2025 | Alvesco |
| Lundbeck LLC | $19.56 | 2024 | Rexulti |
| Ars Pharmaceuticals Operations, INC. | $18.62 | 2025 | Neffy |
| Astellas Pharma US INC | $18.52 | 2023 | Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $16.90 | 2021 | |
| Shield Therapeutics INC | $15.60 | 2025 | |
| Medtronic, INC. | $14.95 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.77 | 2023 | Eliquis |
| Vistapharm, INC. | $14.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lehnert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.